Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 1791 Official Publication of Indian Association of Medical Microbiologists 
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


Year : 1999  |  Volume : 17  |  Issue : 3  |  Page : 125-128

Antifungal susceptibility testing

Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Okhla Phase 1, New Delhi 110 020

Correspondence Address:
A Rattan
Department of Microbiology, New Drug Discovery Research, Ranbaxy Research Laboratories, Okhla Phase 1, New Delhi 110 020

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

ABSTRACT: The incidence of fungal infections has increased dramatically over the past few decades due to the increase in the numbers of the population susceptible to such infections. Newer antifungal agents have increased the therapeutic options thereby leading to the demand for in vitro determination of antifungal susceptibility. But the application of in vitro antifungal susceptibility testing in clinical research and to guidance of antifungal therapy has been limited by a lack of reproducibility and uncertain clinical relevance. NCCLS has described a standardized antifungal susceptibility test method M27A which has good inter and intralaboratory reproducibility. A modification of this method for susceptibility testing of filamentous fungi appears promising. Correlation between MICs determined by this method with clinical response to therapy are beginning to emerge, most notably in relation to fluconazole therapy for oropharyngeal candidosis associated with infection with HIV. Although considerable work remains to be done, the available data suggest that routine susceptibility testing of fungi will become meaningful for clinical decision making in the foreseeable future.

[PDF Not available]*

Print this article     Email this article

2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04